Merck & Company Inc (MRK) is a leading drug manufacturers - general business with stocks listed in the US. It opened the day at US$102.85 after a previous close of US$102.48. During the day the price has varied from a low of USD102.66 to a high of USD103.6761. The latest price was USD103.46 (25 minute delay). Merck-and-Company is listed on the NYSE. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
Low costs
Our top pick for
Dividend investing
Merck-and-Company's shares were split on a 1048:1000 basis on 3 June 2021. So if you had owned 1000 shares the day before the split, the next day you would own 1048 shares. This wouldn't directly have changed the overall worth of your Merck-and-Company shares – just the quantity. However, indirectly, the new 4.6% lower share price could have impacted the market appetite for Merck-and-Company shares which in turn could have impacted Merck-and-Company's share price.
| Open | US$102.85 |
|---|---|
| High | US$103.6761 |
| Low | US$102.66 |
| Close | US$103.46 |
| Previous close | US$102.48 |
| Change | US$0.98 |
| Change % | 0.9563% |
| Volume | 6,717,279 |
| 52-week range | US$99.14 - US$118.0511 |
|---|---|
| 50-day moving average | US$103.5912 |
| 200-day moving average | US$108.5413 |
| Target price | US$114.02 |
| PE ratio | 56.5944 |
| Dividend yield | US$2.88 (2.87%) |
| Earnings per share (TTM) | US$1.8 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $103.46
| 1 week (2023-11-24) | 1.56% |
|---|---|
| 1 month (2023-11-02) | 0.59% |
| 3 months (2023-09-01) | -5.81% |
| 6 months (2023-06-02) | -8.05% |
| 1 year (2022-12-02) | -5.98% |
|---|---|
| 2 years (2021-12-02) | 40.02% |
| 3 years (2020-12-02) | 32.50% |
| 5 years (2018-11-30) | 36.66% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Merck-and-Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merck-and-Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Merck-and-Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 57x. In other words, Merck-and-Company shares trade at around 57x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Merck-and-Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.359. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merck-and-Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Merck-and-Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$12.9 billion (£10.2 billion).
The EBITDA is a measure of a Merck-and-Company's overall financial performance and is widely used to measure a its profitability.
Over the last 12 months, Merck-and-Company's shares have ranged in value from as little as US$99.14 up to US$118.0511. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Merck-and-Company's is 0.375. This would suggest that Merck-and-Company's shares are less volatile than average (for this exchange).
| Revenue TTM | US$59.3 billion |
|---|---|
| Operating margin TTM | 36.49% |
| Gross profit TTM | US$42.1 billion |
| Return on assets TTM | 5.4% |
| Return on equity TTM | 10.77% |
| Profit margin | 7.77% |
| Book value | 16.269 |
| Market capitalisation | US$258.1 billion |
TTM: trailing 12 months
Dividend payout ratio: 94.5% of net profits
Recently Merck-and-Company has paid out, on average, around 94.5% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.87% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck-and-Company shareholders could enjoy a 2.87% return on their shares, in the form of dividend payments. In Merck-and-Company's case, that would currently equate to about $2.88 per share.
Merck-and-Company's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Merck-and-Company's most recent dividend payout was on 6 October 2023. The latest dividend was paid out to all shareholders who bought their shares by 14 September 2023 (the "ex-dividend date").
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Merck-and-Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 28.35
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Merck-and-Company's overall score of 28.35 (as at 01/01/2019) is nothing to write home about – landing it in it in the 47th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Merck-and-Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.15/100
Merck-and-Company's environmental score of 3.15 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 15.55/100
Merck-and-Company's social score of 15.55 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 12.65/100
Merck-and-Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Merck-and-Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Merck-and-Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Merck-and-Company hasn't always managed to keep its nose clean.
Merck & Company Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 28.35 |
|---|---|
| Total ESG percentile | 47.16 |
| Environmental score | 3.15 |
| Environmental score percentile | 4 |
| Social score | 15.55 |
| Social score percentile | 4 |
| Governance score | 12.65 |
| Governance score percentile | 4 |
| Level of controversy | 3 |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors, as well as a clinical trial collaboration and supply agreement with Phanes Therapeutics, Inc. to evaluate PT886 in combination with KEYTRUDA for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas, as well as a development and commercialization agreement with Daiichi Sankyo Company, Limited to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Looking for the best performing stocks in Australia? We update this list weekly.
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Steps to owning and managing Microsoft shares from in Australia.
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
Learn about the money market and everyday consumer money market products.
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
Follow these tips to find the best share trading platform for you.
